Treatment of Clostridioides Difficile Infection: from Guidelines to Clinical Practice

Overview

Journal Rev Esp Quimioter

Specialty Pharmacology

Date 2022 Oct 26

PMID 36285868

Authors

E Merino

M Salavert

Affiliations

Soon will be listed here.

Abstract

The Clostridioides difficile Infection (CDI) treatment guidelines were published in 2021; however, the incorporation of these recommendations into clinical practice was rather irregular and inconsistent. The differences in the implementation of these new guidelines were due, in part, to the variety in the different professionals who provided patient care, as well as to the issues involved in either their accessibility or availability or both. The main requirements for implementation include appropriate reflection on patient stratification, drug positioning, accessibility to drugs, as well as the organization of structured clinical pathways that can facilitate the functionality and evaluation of the management of CDI.

Citing Articles

Comparative effectiveness of treatments for recurrent infection: a network meta-analysis of randomized controlled trials.

Duo H, Yang Y, Zhang G, Chen Y, Cao Y, Luo L Front Pharmacol. 2024; 15:1430724.

PMID: 39484168 PMC: 11525118. DOI: 10.3389/fphar.2024.1430724.

References

Escudero-Sanchez R, Ruiz-Ruizgomez M, Fernandez-Fradejas J, Garcia Fernandez S, Samperio M, Yuste A . Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Infection. J Clin Med. 2020; 10(1). PMC: 7792623. DOI: 10.3390/jcm10010002. View

van Rossen T, van Dijk L, Heymans M, Dekkers O, Vandenbroucke-Grauls C, van Beurden Y . External validation of two prediction tools for patients at risk for recurrent infection. Therap Adv Gastroenterol. 2021; 14:1756284820977385. PMC: 7797589. DOI: 10.1177/1756284820977385. View

Chen J, Gong C, Hitchcock M, Holubar M, Deresinski S, Hay J . Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clin Microbiol Infect. 2021; 27(10):1448-1454. PMC: 9478885. DOI: 10.1016/j.cmi.2021.04.004. View

Lawal A, Rotter T, Kinsman L, Machotta A, Ronellenfitsch U, Scott S . What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic review. BMC Med. 2016; 14:35. PMC: 4765053. DOI: 10.1186/s12916-016-0580-z. View

Jabbour M, Newton A, Johnson D, Curran J . Defining barriers and enablers for clinical pathway implementation in complex clinical settings. Implement Sci. 2018; 13(1):139. PMC: 6233585. DOI: 10.1186/s13012-018-0832-8. View

Escudero-Sanchez R, Valencia-Alijo A, Cuellar Tovar S, Merino-de Lucas E, Garcia Fernandez S, Gutierrez-Rojas A . Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes. Infection. 2021; 49(3):475-482. DOI: 10.1007/s15010-020-01567-5. View

Servick K . Alternatives to fecal transplants near approval. Science. 2022; 375(6579):368-369. DOI: 10.1126/science.ada0539. View

Bouza E, Cobo J, Rodriguez-Hernandez M, Salavert M, Horcajada J, Iribarren J . Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study. Rev Esp Quimioter. 2021; 34(2):126-135. PMC: 8019457. DOI: 10.37201/req/135.2020. View

Nelson R, Suda K, Evans C . Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev. 2017; 3:CD004610. PMC: 6464548. DOI: 10.1002/14651858.CD004610.pub5. View

10.

Appaneal H, Caffrey A, LaPlante K . What Is the Role for Metronidazole in the Treatment of Clostridium difficile Infection? Results From a National Cohort Study of Veterans With Initial Mild Disease. Clin Infect Dis. 2018; 69(8):1288-1295. DOI: 10.1093/cid/ciy1077. View

11.

Gentry C, Campbell D, Williams R . Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study. Int J Antimicrob Agents. 2021; 57(3):106282. DOI: 10.1016/j.ijantimicag.2021.106282. View

12.

Gerding D, Kelly C, Rahav G, Lee C, Dubberke E, Kumar P . Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. Clin Infect Dis. 2018; 67(5):649-656. PMC: 6093994. DOI: 10.1093/cid/ciy171. View

13.

van Rossen T, Ooijevaar R, Vandenbroucke-Grauls C, Dekkers O, Kuijper E, Keller J . Prognostic factors for severe and recurrent Clostridioides difficile infection: a systematic review. Clin Microbiol Infect. 2021; 28(3):321-331. DOI: 10.1016/j.cmi.2021.09.026. View

14.

Cobo J, Merino E, Martinez C, Cozar-Llisto A, Shaw E, Marrodan T . Prediction of recurrent clostridium difficile infection at the bedside: the GEIH-CDI score. Int J Antimicrob Agents. 2017; 51(3):393-398. DOI: 10.1016/j.ijantimicag.2017.09.010. View

15.

Rinaldi A, Reed E, Stevenson K, Coe K, Smith J . Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile. J Clin Pharm Ther. 2021; 46(4):993-998. DOI: 10.1111/jcpt.13387. View